The mammalian target of rapamycin (mTOR) assembles a signaling network essential for the regulation of cell growth, which has emerged as a major target of anticancer therapies. The tuberous sclerosis complex 1 and 2 (TSC1/2) proteins and their target, the small GTPase Rheb, constitute a key regulatory pathway upstream of mTOR. Phospholipase D (PLD) and its product phosphatidic acid are also upstream regulators of the mitogenic mTOR signaling. However, how the TSC/Rheb and PLD pathways interact or integrate in the rapamycin-sensitive signaling network has not been examined before. Here, we find that PLD1, but not PLD2, is required for 
M
ammalian target of rapamycin (mTOR) is a Ser/Thr kinase serving a pivotal role in the regulation of cell growth and proliferation by mediating nutrient availability and mitogenic signals (1) (2) (3) . The best characterized downstream effectors of the rapamycin-sensitive mTOR signaling complex (mTORC1) are the ribosomal S6 kinase 1 (S6K1) and the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), both of which are critically involved in the regulation of protein synthesis in response to mitogenic stimuli, nutrient sufficiency, and cellular energy levels (1) (2) (3) . The lipid second messenger phosphatidic acid (PA) has been found to mediate mitogenic activation of mTOR signaling (4, 5) . As one of the enzymes responsible for the production of cellular PA, phospholipase D (PLD) is an upstream regulator in the mTOR pathway in both mitogenesis (6, 7) and the mechanical stimulation of skeletal muscle growth (8) .
PLD generates PA and choline by hydrolyzing phosphatidylcholine (PC) in response to a variety of stimuli (9, 10) . Two major isoforms of PC-specific PLD have been identified in mammals, namely PLD1 and PLD2. PLD1 can be directly activated by three families of proteins, the conventional protein kinase C (cPKC), Rho GTPases (RhoA, Cdc42, and Rac1), and ARF GTPases (9, 10) , whereas PLD2 exhibits a high basal activity. Previously, we have shown that PLD1 is required for mTOR signaling and cell size regulation and that Cdc42 activates S6K1 by regulating PLD1 (6) .
The tumor suppressors tuberous sclerosis complex 1 and 2 (TSC1/2) are negative regulators of mTOR signaling in the control of cell size and cell cycle progression (11, 12) . The GTPase-activating protein (GAP) activity of TSC2 targets the small G protein Rheb (Ras homologue enriched in brain), which activates mTOR signaling and regulates cell size (11, 12) . The TSC/Rheb pathway appears to be a signal integrator at which multiple inputs including cellular energy levels, growth factors, and hypoxia converge (3) . Despite the initial speculation of the involvement of nutrient signals, TSC1/2 was not found to be absolutely essential in mediating amino acid sufficiency signals (13) (14) (15) . The mTOR-associating protein Raptor may mediate nutrient-sensing signals (16) , and hVps34, a class III PI3K, has also emerged as a component of the amino acidregulated mTOR pathway parallel to TSC/Rheb (13, 17) . The current model of Rheb activation of mTOR involves direct interaction between these two proteins independent of Rheb GTP loading and activation of mTOR kinase by Rheb in a GTP-dependent manner (14, 18) . In this study, we have identified another mechanism of Rheb action in the amino acidsensing mTOR signaling pathway. We find that PLD1 is required for Rheb activation of mTORC1 and that the TSC/Rheb pathway and amino acid sufficiency are upstream regulators of PLD in cells. Furthermore, we present evidence that Rheb binds and activates PLD1 in vitro in a GTP-dependent manner. Our observations strongly suggest that PLD1 is a bona fide effector for Rheb in the amino acid-sensing mTOR signaling pathway.
Results

PLD1 Is
Required for Rheb Activation of mTOR Signaling. To examine the relationship between TSC/Rheb and PLD pathways, which are both upstream regulators of mTORC1 signaling, we probed the requirement of PLD in Rheb-mediated S6K1 activation by using 1-butanol, an inhibitor of PA production through PLD. We reported previously (4) that 1-butanol at low concentrations (e.g., 0.5%) inhibits serum-stimulated S6K1 activation by Ϸ60%. As shown in Fig. 1A , Rheb-stimulated S6K1 activation, as well as T389-S6K1 phosphorylation, in HEK293 cells was also inhibited by 1-butanol, the degree of which was comparable to that of inhibition of serum stimulation. As a negative control, 2-butanol had minimal effect. This observation suggested that PLD might be involved in the activation of S6K1 by Rheb. However, the relatively nonspecific nature of 1-butanol as an inhibitor called for more definitive evidence for the involvement of PLD.
Of the two known mammalian PLD isoforms, we previously showed that PLD1 is required for serum-stimulated S6K1 activation in HEK293 cells (6) , although PLD2's role in mTOR signaling is also possible (7, 19) . To test whether either PLD mediates Rheb activation of S6K1, we knocked down PLD1 and PLD2 separately in HEK293 cells via lentivirus-mediated shRNA expression. As shown in Fig. 1B , knockdown of PLD1 led to a reduction of S6K1 activation (as measured by T389 phosphorylation) in response to Rheb overexpression. The different levels of PLD1 knockdown resulting from the two independent shRNAs correlated closely with the degrees of reduction of S6K1 activation upon Rheb overexpression, confirming the knockdown specificity. Exogenous PA, the product of PLD, rescued T389 phosphorylation in the presence of PLD1 knockdown (Fig.  1B, last two lanes) , suggesting that the function of PLD1 in Rheb activation of S6K1 is most likely dependent on the phospholipase activity. In contrast, knockdown of PLD2 by two independent shRNAs had no effect on Rheb activation of S6K1 (Fig. 1C) . Although we could not directly assess the degree of PLD2 protein knockdown due to the lack of an effective antibody and/or low abundance of PLD2 in these cells, the mRNA levels of PLD2 were reduced by 90% and 60%, making it highly likely that the protein would be dramatically reduced based on our experience with knockdown of many other genes. Taken together, these results strongly suggest that PLD1, but not PLD2, is required for Rheb-mediated S6K1 activation through the production of PA. Of note, we have found that PLD1, and not PLD2, also is required for serum-stimulated mTORC1 activation in HEK293 cells (data not shown), as well as the activation of a myogenic mTOR pathway in C2C12 myoblasts (20) .
Rheb Activates PLD1 in Cells. At least two alternative possibilities existed to explain the dependence of Rheb-S6K1 activation on PLD1: Either Rheb was an upstream activator of PLD1 or PLD1 acted in parallel to Rheb in the mTOR signaling network. To probe the possibility that Rheb might be an upstream regulator of PLD1, we asked whether the overexpression of Rheb could activate PLD1. A recombinant HA-tagged PLD1 was transiently expressed in HEK293 cells together with various small G proteins, including WT Rheb, WT Cdc42, and constitutively active Cdc42 (L61), Rap1 (V12), and Rab5A (L79). As we reported previously (6) , the constitutively active Cdc42-L61, but not WT Cdc42, activated PLD1 by Ϸ2-fold in these cells in the absence of any stimulus ( Fig. 2A) . Significantly, the overexpression of WT Rheb activated PLD1 by Ϸ2.5-fold. Rap1-V12 and Rab5A-L79, previously shown to be unable to activate S6K1 when overexpressed in cells (21), did not have any effect on PLD1. Thus, the ability of the small G proteins to activate PLD1 correlated well with their capacity to activate S6K1.
Two Rheb mutants, C181S and D60K, were examined for their ability to activate PLD1 when overexpressed. Mutation of the CAAX motif (C181S) presumably eliminates farnesylation of Rheb, and this mutant has been reported to have diminished capacity to activate S6K1 (22, 23) . Another mutant, D60K, has been reported to be inactive toward S6K1 (24, 25) . As shown in Fig. 2B , C181S significantly diminished, whereas D60K abolished Rheb's ability to activate PLD1 in cells, and the activities of these two mutants toward PLD1 correlated well with their abilities to activate S6K1. These observations are consistent with the notion that Rheb activates S6K1 via PLD1.
To further validate Rheb's role in the activation of PLD in the cell, we knocked down Rheb in HeLa cells and assessed its effect on serum activation of endogenous PLD. As shown in Fig. 2C , knockdown of Rheb by two independent shRNAs led to diminished PLD activation, accompanied by reduced T389 phosphorylation of S6K1. The effect of Rheb knockdown on S6K1 phosphorylation in HeLa cells is consistent with observations by others (26) . These data suggest that the mitogenic activation of PLD in cells depends on Rheb. TSC2 negatively regulates mTOR signaling by acting as a GAP for Rheb. The ability of Rheb to activate PLD1 prompted us to ask whether the overexpression of TSC2 would have a negative effect on PLD1 activation. As shown in Fig. 3A , the overexpression of TSC2 diminished phorbol 12-myristate 13-acetate (PMA)-stimulated recombinant PLD1 activity and S6K1 activation. A TSC patient-derived, GAP-inactive mutant of TSC2, N1651S (23), had no inhibitory effect on PLD1, suggesting that the GAP activity of TSC2 is involved in its regulation of PLD1. The effect of TSC2 overexpression was modest probably because TSC1 is required for the stabilization and maximal function of TSC2 in cells. However, we were unable to reliably assess the effect of TSC1/TSC2 coexpression on PLD1 activation due to technical difficulties in coexpressing those three recombinant proteins. Alternatively, PMA as a stimulus may activate a significant pool of PLD1 (e.g., through cPKC) in the cells independent of the Rheb-mTOR pathway. It should be noted that we used PMA in these experiments because of its robust activation of PLD1, which allowed for the detection of the modest effect of TSC2 overexpression. Serum stimulation would be performed for all other experiments described later because serum (like insulin) is a well established mitogen for the activation of the PI3K-TSC-mTOR pathway.
To better assess the role of TSC in the potential activation of PLD by Rheb, we knocked down TSC2 in HEK293 cells and examined the cellular PLD activity. As shown in Fig. 3B , TSC2 knockdown led to a significant elevation in PLD activity in serum-starved cells, and the degree of increase was correlated with the knockdown efficiency by two independent shRNAs. Because of technical hurdles involved in quantifying recombinant PLD1 activity in TSC2 knockdown and PLD1 overexpressed cells, we took advantage of the TSC2 Ϫ/Ϫ or TSC2
Eker rat embryonic fibroblasts (EEFs) (27) , in which we transiently expressed HA-PLD1. Under serum-starvation conditions, the recombinant PLD1 activity was undetectable in TSC2 ϩ/ϩ cells and was significantly activated in TSC2 Ϫ/Ϫ cells (Fig. 3C) . In contrast, the recombinant PLD2 activity was comparable in TSC2 ϩ/ϩ and TSC2 Ϫ/Ϫ cells [supporting information (SI) Fig. S1 ]. Collectively, these observations cogently state the model that Rheb activates PLD1 in cells.
Regulation of PLD by Signals Upstream of mTOR Signaling. Several upstream signals regulate mTORC1 by impinging on the TSC/ Rheb axis, including cellular energy levels through AMPK and growth factor signaling via the PI3K/Akt pathway (3). To examine the potential roles of PI3K and the cellular energy levels on PLD activation, we performed in vivo PLD assays in HEK293 cells to test the effects of the specific PI3K inhibitor wortmannin and the AMPK activator 2-deoxyglucose on serum stimulation of PLD. As shown in Fig. 4A , serum stimulation activated cellular PLD by Ϸ1.5-fold, comparable to reported serum activation of PLD in other types of cells (28) . This activation was dampened by wortmannin and drastically inhibited by 2-deoxyglucose; similar inhibition of S6K1 T389 phosphorylation was also observed (Fig. 4A ). As expected, rapamycin had no effect on PLD activity, although it abolished S6K1 activation. These observations are consistent with PLD lying downstream of TSC/Rheb and upstream of mTOR. Because amino acid sufficiency is essential for mTORC1 signaling, although the exact sensing mechanism is unclear, we examined the requirement of amino acids for PLD activation. A short-term amino acid withdrawal using amino acid-free DMEM significantly suppressed serum stimulation of PLD activation in HEK293 cells, and replenishing amino acids in the deprived cells restored PLD activation (Fig. 4B) . Furthermore, the enhancement of PLD activity by TSC2 knockdown also was inhibited by amino acid deprivation (Fig. 4C) . These results reveal regulation of PLD by amino acid availability and suggest that PLD may partly mediate amino acid sensing in the mTOR pathway. Because exogenous PA is not able to override the amino acid requirement for S6K1 activation (4), amino acid signals likely impinge on other targets in the mTORC1 pathway in addition to PLD.
Rheb Binds PLD1. Taken together, our observations placed PLD1 downstream of Rheb on a linear pathway. To dissect the mechanisms by which Rheb may regulate PLD1, we asked whether Rheb and PLD1 physically interact. GST pulldown assays were performed with lysates of HEK293 cells transiently expressing GST-Rheb or GST. As shown in Fig. 5A , GST-Rheb, but not GST, associated with endogenous PLD1. GST-Rheb also interacted with mTOR, as reported by others previously (14, 18) .
To address whether GTP loading of Rheb is required for the Rheb-PLD1 interaction, in vitro GST pulldown assays were performed with bacterially expressed and purified GST fusion proteins and lysates of CHO cells expressing HA-PLD1. The GST proteins were loaded with GTP␥S or GDP␤S before incubation with HA-PLD1-containing lysates and subsequent glutathione pulldown. GST-Cdc42, a well characterized PLD1-binding protein, was used as a positive control. As shown in Fig.  5B , GST-Rheb pulled down PLD1 in a GTP-dependent manner. Binding of mTOR to GST-Rheb also was observed, and it was independent of GTP loading, which is consistent with previous reports (14, 18) .
Rheb Activates PLD1 in Vitro. The physical interaction between Rheb and PLD1 prompted us to ask whether Rheb could directly activate PLD1 in vitro. Stably expressed HA-PLD1 was immunoprecipitated from serum-starved cells and incubated with bacterially purified GST-Rheb in the presence or absence of GTP␥S. As shown in Fig. 6A , PLD1 was markedly activated by GST-Rheb, and this activation was absolutely dependent on the presence of GTP␥S. The degree of PLD1 activation by Rheb was somewhat higher than that by GST-Cdc42. Neither H-Ras nor RalA was able to activate PLD1. The lack of activation by RalA, despite its reported interaction with PLD1, is consistent with observations by others (29) . Taken together, Rheb is likely a direct activator of PLD1 and is at least as potent as Cdc42.
Discussion
As an essential growth-regulating signaling network and an attractive target of anticancer drug development in recent years, the molecular wiring of the rapamycin-sensitive pathways is of tremendous interest and remains an intriguing puzzle. Our study described here has revealed a surprising connection between two previously established signaling pathways in this intricate network. We have demonstrated that PLD1 is required for Rheb activation of mTOR signaling to S6K1 and that the TSC/Rheb pathway controls PLD1 activation in cells. We have further provided biochemical evidence that Rheb binds and activates PLD1 in a GTP-dependent manner. In conclusion, our findings strongly suggest that PLD1 is a bona fide effector for Rheb (Fig.  6B) , filling a sizable gap in our knowledge of the signal transduction by the nutrient-sensing and growth-promoting mTOR network. Previously found to mediate mitogenic signals in the mTOR pathway (4, 6), PLD1 may also receive nutrient signals as suggested by the sensitivity of PLD1 activity to amino acid deprivation (Fig. 4 B and C) . Amino acid signals appear to impinge on the mTORC1 pathway at least at two distinct levels. On the one hand, depletion of amino acids abolishes insulininduced GTP-loading of Rheb (15) . On the other hand, in the presence of activated Rheb, as found in TSC2 knockout cells, amino acid deprivation can still block mTOR signaling likely via inhibition of the hVps34 pathway (13, 17) . This dual level of regulation is fully consistent with our current and previous observations: PLD activation by serum, as well as by TSC2 knockdown, requires amino acid sufficiency, yet exogenous PA cannot override the requirement for amino acids in the activation of S6K. These situations should be discriminated from experiments in which Rheb is overexpressed. Under such conditions, Rheb is fully GTP loaded and activates mTOR even in the absence of amino acids or mitogens (21, 23, 26, 30, 31 ). Therefore, it is not surprising that the interaction between overexpressed GST-Rheb and endogenous PLD1 (Fig. 5A ) in the GST pulldown assays performed with HEK293 cell lysates was not affected by amino acid deprivation or serum starvation of the cells (Fig. S2) . How exactly PLD1 receives amino acid signals is of obvious interest. Although regulation of PLD1 binding to and/or activation by the GTP loading of Rheb in cells remains a strong possibility to be further examined, a potential relationship between PLD1 and hVps34 also merits future investigation (Fig. 6B) .
While this article was in its final stage of preparation, a report appeared, revealing another direct target of Rheb-FKBP38, an endogenous inhibitor of mTOR (32) . Rheb is shown to bind FKBP38 in a GTP-dependent and amino acid-sensitive manner, and it activates mTOR by displacing FKBP38. Interestingly, both PA, the product of PLD, and FKBP38 bind a region of mTOR that contains the rapamycin-FKBP12-binding (FRB) domain (4, 32) . It is tempting to speculate that PA also may function to displace FKBP38 from mTOR and that Rheb activation of PLD1 and binding of FKBP38 synergize to achieve complete removal of FKBP38 and maximal activation of mTOR. Alternatively, PA may be necessary for mTOR activation after FKBP38 is removed; Rheb may play a dual role in eliminating the inhibitor and supplying the activator, and the two events may take place independently, but concurrently, to activate mTOR.
Three classes of proteins directly interact with and activate PLD1: cPKC, ARF, and Rho. We have now identified Rheb as a new regulator of PLD1. PLD1 appears indispensable for Rheb activation of the mTOR pathway (Fig. 1B) and presumably cell size regulation. We found that Rheb activated PLD1 expressed and immunoprecipitated from mammalian cells, but not PLD1 purified from insect cells (data not shown), implying that a yet-to-be-identified cofactor or certain mammalian cell-specific posttranslational modification of PLD1 is required for the activation of PLD1 by Rheb. Thus, several intriguing questions remain to be addressed: Does Rheb compete for or synergize with the other known regulators in binding and activating PLD1? How does Rheb cross-talk with the other regulators in a cell to regulate PLD1 and mTOR signaling? Is Rheb involved in PLD1 functions other than cell size control, such as vesicle trafficking and cytoskeleton reorganization? These questions will guide future research efforts to reveal a clearer picture of the TSCRheb-PLD regulatory network.
Materials and Methods
Antibodies and Other Reagents. The antibodies were obtained from the following sources: anti-FLAG M2 from Sigma; anti-HA (16B12) and anti-Myc (9E10.2) from Covance; anti-phospho-T389-S6K1, anti-PLD1, and anti-Rheb from Cell Signaling; anti-tubulin from Abcam; and anti-mTOR (FRB domain) was generated at the University of Illinois at Urbana-Champaign Biotechnology Center. Rapamycin and wortmannin were purchased from Calbiochem. Insulin, PMA, 2-deoxyglucose, 1-butanol, 2-butanol, polybrene, and puromycin were from Sigma. GTP␥S and GDP␤S trilithium salts were from Roche.
[Choline-methyl-3 H] dipalmitoyl-phosphatidylcholine ( 3 H-DPPC) was from Amersham. [9, H]-palmitic acid was from PerkinElmer. All other lipids were from Avanti.
Plasmids. D60K mutation was introduced into FLAG-Rheb (see below) by using QuikChangeII Kit (Stratagene). pGEX-Rheb was generated by inserting the PCR product of Rheb into pGEX-4T. pRK7-GST-Rheb was made by inserting the PCR product of GST via XbaI and BamHI sites into pRK7-FLAG-Rheb. Myc-S6K1 and HA-PLD1 were described previously (6) . The following plasmids were generous gifts from various laboratories: plasmids for mammalian expression of FLAG-tagged Rheb, Rheb-C181S, TSC1, TSC2, TSC2-N1651S, and bacterial expression vector for GST-Cdc42 were from J. Blenis (Harvard Medical School, Boston) (33) . FLAG-Rab5A-L79 and FLAG-Rap1-V12 were from K. L. Guan (University of Michigan School of Medicine, Ann Arbor, MI) (21) . Bacterial expression plasmids for GST-H-Ras and GST-RalA were from L. A. Quilliam (Indiana University School of Medicine, Indianapolis) (34).
Cell Culture and Transfection. HEK293 cells were grown in DMEM containing 10% FBS at 37°C with 5% CO 2. All transient transfections were carried out with PolyFect (Qiagen) when the cells were 60 -70% confluent. The amount of DNA transfected was between 0.5 and 1.5 g for each plasmid, adjusted to ensure equal expression of the recombinant protein to be compared within each experiment. Various treatments were applied to the cells 24 h after transfection. Serum starvation of cells was carried out in serum-free DMEM overnight. Amino acid deprivation was achieved by incubating cells in amino acid-free DMEM (HyClone) for 1 h. For PA stimulation of the cells, 42 l of 1-palmitoyl 2-oleoyl phosphatidic acid in chloroform (25 mg/ml) was dried under nitrogen, resuspended in 250 l of DPBS, and sonicated in a water bath sonicator (80 watts) for 5 min. Freshly prepared PA vesicles were added to the cell medium to a final concentration of 100 M. CHO cells stably expressing HA-PLD1 under the control of the tetracycline promoter (a generous gift from M. Frohman, State University of New York, Stony Brook, NY) (35) were grown in F-12 medium containing 10% FBS, 10 g/ml blasticidin, and 300 g/ml zeocin at 37°C with 5% CO 2. At the cell density of 60 -70%, 1 g/ml doxycycline was added in the medium to induce HA-PLD1 expression. TSC2 ϩ/ϩ and TSC2 Ϫ/Ϫ EEF cells (a generous gift from R. S. Yeung, University of Washington, Seattle) (27) were cultured in DME/F-12 medium with 10% FBS under 5% CO 2. Nucleofection was used to introduce DNA into the EEF cells (Amaxa nucleofector, program D23, Kit L).
Lentivirus-Mediated RNAi. All shRNA was purchased from Sigma-Aldrich (Mission shRNA). Lentivirus packaging and infection were performed as described previously (36) . See SI Materials and Methods for target sequences.
Quantitative RT-PCR. Quantitative RT-PCR was performed as described previously (36) . The primers used were: hPLD2 forward, 5Ј-TCCATCCAGGCCATTCTGCAC; hPLD2 reverse, 5Ј-CGTTGCTCTCAGCCATGTCTTG; ␤-actin forward, 5Ј-GCACTCT-TCCAGCCTT CCT; and ␤-actin reverse, 5Ј-AGGTCTTTGCGGATGTCCAC. S6 Kinase Assay. Myc-S6K1 was immunoprecipitated from transfected cells and subjected to in vitro S6 kinase assay by using a peptide substrate as described previously (6) .
In Vivo PLD Assay. In vivo PLD activity was measured in a transphosphatidylation assay adopted from methods published previously (37, 38) and modified as described previously (20) . To calculate recombinant PLD1 activity, the PLD activity in cells transfected with empty vector (pCDNA3) was subtracted from the activity in transfected cells under the same conditions. For EEF cell nucleofection, 1 ϫ 10 6 cells were electroporated with 5 g pCDNA3 or HA-PLD1, seeded into a six-well plate, and cultured for 2 days, followed by serum starvation in DME/F-12 with 0.1% FBS overnight. PLD1 activity was measured as above and normalized against HA-PLD1 band intensity on Western blots (quantified by using Image J).
GST Pulldown Assays. GST fusions of small GTPases were purified from bacteria by using glutathione Sepharose affinity chromatography. The purified GSTGTPase proteins (5 g each) were first stripped of nucleotides by incubation in 5 mM EDTA (in PBS) on ice for 15 min, followed by incubating with 20 mM MgCl 2and 100 M guanine nucleotide (GTP␥S or GDP␤S) in 30 l for 30 min at 4°C and then for 10 min at 30°C. The nucleotide-loaded protein was then mixed with 20 l of CHO cell lysates [lysis buffer: 40 mM Tris⅐Cl (pH 7.2), 1 mM Na3VO4, 25 mM NaF, 25 mM b-glycerophosphate, 2 mM EDTA, 2 mM EGTA, 1 mM DTT, 1 mM PMSF, and 0.3% Triton X-100] containing HA-PLD1 (see above) and incubated at 30°C for 30 min. Glutathione Sepharose beads were added to the mixture and gently rocked at 4°C for 1 h, followed by washing with lysis buffer and eluting in SDS sample buffer containing 8 M urea. For in vivo pulldown, GST-or GST-Rheb-transfected HEK293 cells were lysed, and the lysates were incubated with glutathione Sepharose beads, followed by washing with PBS.
In Vitro PLD Assay. In vitro PLD assays were performed by measuring the release of [ 3 H]choline modified from previously reported methods (39, 40) . HA-PLD1 was immunoprecipitated from doxycycline-treated and serumstarved CHO cells described earlier and washed in lysis buffer with 1% Nonidet P-40. The immunocomplex was resuspended in 50 l of reaction buffer [50 mM Hepes (pH 7.5), 3 mM EGTA, 80 mM KCl, 1 mM DTT, 2 mM CaCl2, and 3 mM MgCl 2], to which 5 g of GST fusion protein with or without GTP␥S (final concentration 30 M) were added and incubated at 37°C for 10 min. The PLD reaction was initiated by adding the substrate in the form of phospholipid vesicles composed of 1,2-dipalmitoyl-sn-glycero-3-phosphatidylethanomine, PIP2, and dipalmitoyl PC (DPPC) in a molar ratio of 16:1.4:1. [ 3 H]DPPC was included at 20,000 cpm per assay. After incubation at 37°C for 30 min, the reaction was stopped by the addition of 200 l of 10% trichloroacetic acid and 100 l of 10 mg/ml BSA, followed by centrifugation at 3,000 ϫ g for 10 min at 4°C. A 0.3-ml aliquot of the supernatant was removed and analyzed by liquid scintillation counting.
